Caring Brands, Inc. (NASDAQ: CABR) has closed its underwritten U.S. public offering of 1,000,000 shares of common stock at $4.00 per share, generating gross proceeds of approximately $4 million before underwriting discounts and expenses. The completion of this offering marks the company's uplisting to the Nasdaq Capital Market, where its shares began trading on November 13, 2025. This move from the over-the-counter markets to a national exchange signals a significant milestone for the wellness consumer products company, enhancing its visibility and credibility among investors.
The company granted the underwriter a 45-day option to purchase up to 150,000 additional shares to cover any over-allotments. Caring Brands intends to use the net proceeds for general working capital, marketing and sales of its proprietary products, and repayment of certain debt. This infusion of capital is expected to accelerate the commercialization of its product pipeline, which includes treatments for hair loss, eczema, psoriasis, vitiligo, and a jellyfish sting protective suncare line.
According to the press release, the company's method of operation ensures that all products have a scientifically established mechanism of action, efficacy determined through controlled clinical trials, protection by issued and filed patents, and acceptable commercial stability. This rigorous approach differentiates Caring Brands in the competitive OTC and cosmetics market, potentially leading to greater consumer trust and market share.
The uplisting to Nasdaq provides the company with access to a broader investor base and increased liquidity for its shares. For investors, this development underscores the company's growth trajectory and commitment to transparency and regulatory compliance. The full press release is available at https://ibn.fm/vAT68.
More information about Caring Brands and its products can be found on the company's website at https://caringbrands.com/. The offering was managed by a single underwriter, though the underwriter's name was not disclosed in the release.
